$PLX
Protalix BioTherapeutics, Inc.

2022 Q1 Form 10-Q Financial Statement

#000155837022008847 Filed on May 16, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $16.09M $11.32M
YoY Change 42.09% -47.7%
Cost Of Revenue $6.034M $4.765M
YoY Change 26.63% 39.08%
Gross Profit $10.05M $6.555M
YoY Change 53.33% -64.02%
Gross Profit Margin 62.49% 57.91%
Selling, General & Admin $3.154M $3.138M
YoY Change 0.51% -1.54%
% of Gross Profit 31.38% 47.87%
Research & Development $8.767M $7.122M
YoY Change 23.1% -31.12%
% of Gross Profit 87.23% 108.65%
Depreciation & Amortization $270.0K $286.0K
YoY Change -5.59% -23.94%
% of Gross Profit 2.69% 4.36%
Operating Expenses $11.92M $10.26M
YoY Change 16.19% -24.15%
Operating Profit -$1.870M -$3.705M
YoY Change -49.53% -178.95%
Interest Expense -$420.0K -$1.820M
YoY Change -76.92% -39.93%
% of Operating Profit
Other Income/Expense, Net -$416.0K -$1.821M
YoY Change -77.16% -39.82%
Pretax Income -$2.286M -$5.480M
YoY Change -58.28% -428.14%
Income Tax
% Of Pretax Income
Net Earnings -$2.286M -$5.475M
YoY Change -58.25% -428.43%
Net Earnings / Revenue -14.21% -48.37%
Basic Earnings Per Share -$0.05 -$0.14
Diluted Earnings Per Share -$0.05 -$0.14
COMMON SHARES
Basic Shares Outstanding 45.84M 39.93M
Diluted Shares Outstanding 45.84M 39.93M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $16.90M $19.80M
YoY Change -14.65% 39.44%
Cash & Equivalents $16.89M $19.83M
Short-Term Investments
Other Short-Term Assets $1.123M $1.754M
YoY Change -35.97% -93.04%
Inventory $16.59M $13.92M
Prepaid Expenses
Receivables $5.908M $4.599M
Other Receivables $0.00 $0.00
Total Short-Term Assets $56.54M $90.70M
YoY Change -37.66% 56.92%
LONG-TERM ASSETS
Property, Plant & Equipment $4.894M $4.828M
YoY Change 1.37% -54.88%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.100M $1.800M
YoY Change 16.67% -87.5%
Total Long-Term Assets $11.85M $12.09M
YoY Change -2.03% -51.82%
TOTAL ASSETS
Total Short-Term Assets $56.54M $90.70M
Total Long-Term Assets $11.85M $12.09M
Total Assets $68.39M $102.8M
YoY Change -33.47% 24.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.900M $6.400M
YoY Change 23.44% -31.91%
Accrued Expenses $1.200M $1.400M
YoY Change -14.29% 27.27%
Deferred Revenue $11.80M $2.560M
YoY Change 360.98%
Short-Term Debt $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $55.40M
YoY Change
Total Short-Term Liabilities $35.33M $80.86M
YoY Change -56.31% 69.88%
LONG-TERM LIABILITIES
Long-Term Debt $28.00M $0.00
YoY Change -100.0%
Other Long-Term Liabilities $12.60M $26.00K
YoY Change 48361.54% -99.82%
Total Long-Term Liabilities $40.55M $7.427M
YoY Change 445.93% -88.76%
TOTAL LIABILITIES
Total Short-Term Liabilities $35.33M $80.86M
Total Long-Term Liabilities $40.55M $7.427M
Total Liabilities $75.88M $88.29M
YoY Change -14.06% -22.42%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$7.486M $14.50M
YoY Change
Total Liabilities & Shareholders Equity $68.39M $102.8M
YoY Change -33.47% 24.0%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$2.286M -$5.475M
YoY Change -58.25% -428.43%
Depreciation, Depletion And Amortization $270.0K $286.0K
YoY Change -5.59% -23.94%
Cash From Operating Activities -$5.829M -$9.834M
YoY Change -40.73% 38.18%
INVESTING ACTIVITIES
Capital Expenditures $229.0K $386.0K
YoY Change -40.67% 484.85%
Acquisitions
YoY Change
Other Investing Activities $28.00K $28.00K
YoY Change 0.0% -20.0%
Cash From Investing Activities -$16.26M -$30.68M
YoY Change -47.02% -12.53%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $8.575M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 42.11M
YoY Change 9.08%
NET CHANGE
Cash From Operating Activities -5.829M -9.834M
Cash From Investing Activities -16.26M -30.68M
Cash From Financing Activities 42.11M
Net Change In Cash -22.10M 1.565M
YoY Change -1511.95% -143.16%
FREE CASH FLOW
Cash From Operating Activities -$5.829M -$9.834M
Capital Expenditures $229.0K $386.0K
Free Cash Flow -$6.058M -$10.22M
YoY Change -40.72% 42.28%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
45843563
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39933972
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001006281
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-33357
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
PROTALIX BIOTHERAPEUTICS, INC.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
65-0643773
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
2 University Plaza
CY2022Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Hackensack
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07601
CY2022Q1 dei City Area Code
CityAreaCode
201
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
696-9345
CY2022Q1 dei Security12b Title
Security12bTitle
Common stock, $0.001 par value
CY2022Q1 dei Trading Symbol
TradingSymbol
PLX
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NYSEAMER
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
47063300
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16888000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38985000
CY2022Q1 plx Short Term Bank Deposits
ShortTermBankDeposits
16029000
CY2022Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5908000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3442000
CY2022Q1 us-gaap Other Assets Current
OtherAssetsCurrent
1123000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1285000
CY2022Q1 us-gaap Inventory Net
InventoryNet
16594000
CY2021Q4 us-gaap Inventory Net
InventoryNet
17954000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
56542000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
61666000
CY2022Q1 us-gaap Defined Benefit Plan Assets For Plan Benefits Noncurrent
DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
2052000
CY2021Q4 us-gaap Defined Benefit Plan Assets For Plan Benefits Noncurrent
DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
2077000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4894000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4962000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4903000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4960000
CY2022Q1 us-gaap Assets
Assets
68391000
CY2021Q4 us-gaap Assets
Assets
73665000
CY2022Q1 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
7873000
CY2021Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
6986000
CY2022Q1 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
14414000
CY2021Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
16433000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1243000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1207000
CY2022Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
11801000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
8550000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
35331000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
33176000
CY2022Q1 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
27962000
CY2021Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
27887000
CY2022Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
5895000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
11790000
CY2022Q1 us-gaap Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
2496000
CY2021Q4 us-gaap Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
2472000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4193000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4376000
CY2022Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
40546000
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
46525000
CY2022Q1 us-gaap Liabilities
Liabilities
75877000
CY2021Q4 us-gaap Liabilities
Liabilities
79701000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-7486000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-6036000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
68391000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
73665000
CY2022Q1 us-gaap Revenues
Revenues
16085000
CY2021Q1 us-gaap Revenues
Revenues
11320000
CY2022Q1 us-gaap Cost Of Revenue
CostOfRevenue
6034000
CY2021Q1 us-gaap Cost Of Revenue
CostOfRevenue
4765000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8767000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7122000
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3154000
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3138000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1870000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3705000
CY2022Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
618000
CY2021Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
2156000
CY2022Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
202000
CY2021Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
335000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-416000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1821000
CY2021Q1 us-gaap Other Income
OtherIncome
51000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2286000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-5475000
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45843563
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39933972
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-27037000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
37625000
CY2021Q1 plx Stock Issued During Period Value Sales Agreement
StockIssuedDuringPeriodValueSalesAgreement
8575000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
510000
CY2021Q1 plx Share Based Compensation Restricted Stock Awards Net Of Forfeitures
ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
306000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-5475000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
14504000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-6036000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
149000
CY2022Q1 plx Share Based Compensation Restricted Stock Awards Net Of Forfeitures
ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
687000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2286000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-7486000
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2286000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-5475000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
836000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
816000
CY2022Q1 us-gaap Depreciation
Depreciation
270000
CY2021Q1 us-gaap Depreciation
Depreciation
286000
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
198000
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
168000
CY2022Q1 us-gaap Pension And Other Postretirement Benefit Expense
PensionAndOtherPostretirementBenefitExpense
75000
CY2021Q1 us-gaap Pension And Other Postretirement Benefit Expense
PensionAndOtherPostretirementBenefitExpense
42000
CY2022Q1 plx Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement
GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
-10000
CY2021Q1 plx Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement
GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
14000
CY2021Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
51000
CY2022Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
75000
CY2021Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
945000
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-2644000
CY2021Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-3692000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2314000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2282000
CY2022Q1 plx Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
2000
CY2021Q1 plx Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
-42000
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1360000
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
833000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1011000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
575000
CY2021Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-25000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5829000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9834000
CY2022Q1 plx Increase Decrease In Bank Deposits
IncreaseDecreaseInBankDeposits
16000000
CY2021Q1 plx Increase Decrease In Bank Deposits
IncreaseDecreaseInBankDeposits
37835000
CY2021Q1 plx Proceeds From Sale Of Short Term Deposits
ProceedsFromSaleOfShortTermDeposits
7500000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
229000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
386000
CY2021Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
53000
CY2021Q1 plx Increase Decrease In Restricted Deposit
IncreaseDecreaseInRestrictedDeposit
-12000
CY2022Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
28000
CY2021Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
28000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-16257000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-30684000
CY2021Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
4086000
CY2021Q1 plx Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Cost
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost
37625000
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8575000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
42114000
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-11000
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-31000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-22097000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1565000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38985000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18265000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16888000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19830000
CY2022Q1 plx Increase In Liabilities For Property Plant And Equipment
IncreaseInLiabilitiesForPropertyPlantAndEquipment
67000
CY2021Q1 plx Increase In Liabilities For Property Plant And Equipment
IncreaseInLiabilitiesForPropertyPlantAndEquipment
202000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
99000
CY2021Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
122000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
1120000
CY2022Q1 plx Interest Received Net
InterestReceivedNet
36000
CY2021Q1 plx Interest Received Net
InterestReceivedNet
136000
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
33004217
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
26769693
CY2022Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
3066000
CY2021Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
3166000
CY2022Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
3370000
CY2021Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
3262000
CY2022Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
10158000
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
11526000
CY2022Q1 us-gaap Inventory Net
InventoryNet
16594000
CY2021Q4 us-gaap Inventory Net
InventoryNet
17954000

Files In Submission

Name View Source Status
0001558370-22-008847-index-headers.html Edgar Link pending
0001558370-22-008847-index.html Edgar Link pending
0001558370-22-008847.txt Edgar Link pending
0001558370-22-008847-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
plx-20220331.xsd Edgar Link pending
plx-20220331x10q.htm Edgar Link pending
plx-20220331x10q005.jpg Edgar Link pending
plx-20220331x10q006.jpg Edgar Link pending
plx-20220331x10q007.jpg Edgar Link pending
plx-20220331x10q_htm.xml Edgar Link completed
plx-20220331xex31d1.htm Edgar Link pending
plx-20220331xex31d2.htm Edgar Link pending
plx-20220331xex32d1.htm Edgar Link pending
plx-20220331xex32d2.htm Edgar Link pending
plx-20220331_cal.xml Edgar Link unprocessable
plx-20220331_def.xml Edgar Link unprocessable
plx-20220331_lab.xml Edgar Link unprocessable
plx-20220331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending